Activation of toll-like receptor, RAGE and HMGB1 signalling in malformations of cortical development

Brain

Volumn 134, Issue 4, 2011, Pages 1015-1032

  Zurolo, Emanuele ^a   Iyer, Anand ^a   Maroso, Mattia ^a,b   Carbonell, Caterina ^a   Anink, Jasper J ^a   Ravizza, Teresa ^b   Fluiter, Kees ^a   Spliet, Wim G M ^c   Van Rijen, Peter C ^d   Vezzani, Annamaria ^b   Aronica, Eleonora ^a,e  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

epilepsy; focal cortical dysplasia; glioneuronal tumours; inflammation; tuberous sclerosis complex

Indexed keywords

ADVANCED GLYCATION END PRODUCT; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 1BETA; MESSENGER RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4;

ADULT; ARTICLE; ASTROCYTE; AUTOPSY; BRAIN MALFORMATION; CELL LINEAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICAL DYSPLASIA; ENZYME ACTIVATION; EPILEPSY; GIANT CELL; GLIA CELL; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VITRO STUDY; MACROPHAGE; MICROGLIA; NERVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUBEROUS SCLEROSIS;

EID: 79953654332     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr032     Document Type: Article

References (81)

1. Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal Bianco A, Khademi M, et al. Pivotal advance: HMGB1 expression in active lesions of human and experimental multiple sclerosis. J Leukoc Biol 2008; 84: 1248-55.
2. Aravalli RN, Peterson PK, Lokensgard JR. Toll-like receptors in defense and damage of the central nervous system. J Neuroimmune Pharmacol 2007; 2: 297-312.
3. Aronica E, Boer K, Becker A, Redeker S, Spliet WG, van Rijen PC, et al. Gene expression profile analysis of epilepsy-associated gangliogliomas. Neuroscience 2008; 151: 272-92.
4. Aronica E, Boer K, van Vliet EA, Baayen JC, Redeker S, Spliet WGM, et al. Complement activation in experimental and human temporal lobe epilepsy. Neurobiol Disease 2007; 26: 497-511. (Pubitemid 46756320)
5. Aronica E, Gorter J. Gene Expression Profile in Temporal Lobe Epilepsy. Neuroscientist 2007; 13: 1-9.
6. Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller AJ, Yankaya B, Leenstra S, et al. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: opposite regulation of glutamate transporter proteins. Eur J Neurosci 2003; 17: 2106-18. (Pubitemid 36713971)
7. Aronica E, Gorter JA, Redeker S, Ramkema M, Spliet WG, van Rijen PC, et al. Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilepsy. Neuropathol Appl Neurobiol 2005a; 31: 280-91. (Pubitemid 40769527)
8. Aronica E, Gorter JA, Redeker S, van Vliet EA, Ramkema M, Scheffer GL, et al. Localization of breast cancer resistance protein (BCRP) in micro-vessel endothelium of human control and epileptic brain. Epilepsia 2005b; 46: 849-57. (Pubitemid 40847353)
9. Aronica E, Gorter JA, Rozemuller AJ, Yankaya B, Troost D. Interleukin-1 beta down-regulates the expression of metabotropic glutamate receptor 5 in cultured human astrocytes. J Neuroimmunol 2005c; 160: 188-94. (Pubitemid 40248608)
10. Aronica E, Leenstra S, Jansen GH, van Veelen CW, Yankaya B, Troost D. Expression of brain-derived neurotrophic factor and tyrosine kinase B receptor proteins in glioneuronal tumors from patients with intractable epilepsy: colocalization with N-methyl-D-aspartic acid receptor. Acta Neuropathol 2001a; 101: 383-92. (Pubitemid 32372428)
11. Aronica E, Yankaya B, Jansen GH, Leenstra S, van Veelen CW, Gorter JA, et al. Ionotropic and metabotropic glutamate receptor protein expression in glioneuronal tumors from patients with intractable epilepsy. Neuropathol Appl Neurobiol 2001b; 27: 1-16.
12. Aronica EM, Leenstra S, Jansen G, van Veelen CW, Yankaya B, Troost D. Expression of BDNF and Tyrosine kinase B (TrkB) receptor proteins in glioneuronal tumors from patients with intractable epilepsy: colocaliza-tion with NMDA receptor. Acta Neuropathol 2001c; 101: 383-92. (Pubitemid 32372428)
13. Babcock AA, Wirenfeldt M, Holm T, Nielsen HH, Dissing-Olesen L, Toft-Hansen H, et al. Toll-like receptor 2 signaling in response to brain injury: an innate bridge to neuroinflammation. J Neurosci 2006; 26: 12826-37. (Pubitemid 44904578)
14. Bianchi ME. HMGB1 loves company. J Leukoc Biol 2009; 86: 573-6.
15. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220: 35-46. (Pubitemid 350045574)
16. Bianchi ME, Manfredi AA. Immunology. Dangers in and out. Science 2009; 323: 1683-4.
17. Boer K, Crino PB, Gorter JA, Nellist M, Jansen FE, Spliet WG, et al. Gene Expression Analysis of Tuberous Sclerosis Complex Cortical Tubers Reveals Increased Expression of Adhesion and Inflammatory Factors. Brain Pathol 2009; 20: 704-19.
18. Boer K, Jansen K, Nellist M, Redeker M, van den Ouweland AMW, Spliet WGM, et al. Inflammatory processes in cortical tubers and sub-ependymal giant cell tumors of tuberous sclerosis complex. Epilepsy Res 2008; 78: 7-21. (Pubitemid 350296774)
19. Boer K, Spliet WG, van Rijen PC, Redeker S, Troost D, Aronica E. Evidence of activated microglia in focal cortical dysplasia. J Neuroimmunol 2006; 173: 188-95.
20. Bowman CC, Rasley A, Tranguch SL, Marriott I. Cultured astrocytes express toll-like receptors for bacterial products. Glia 2003; 43: 281-91. (Pubitemid 37047684)
21. Bsibsi M, Ravid R, Gveric D, van Noort JM. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002; 61: 1013-21. (Pubitemid 35278723)
22. Budde BS, Namavar Y, Barth PG, Poll-The BT, Nurnberg G, Becker C, et al. tRNA splicing endonuclease mutations cause pontocerebellar hypoplasia. Nat Genet 2008; 40: 1113-8.
23. Carpentier PA, Begolka WS, Olson JK, Elhofy A, Karpus WJ, Miller SD. Differential activation of astrocytes by innate and adaptive immune stimuli. Glia 2005; 49: 360-74. (Pubitemid 40222914)
24. Chavakis E, Hain A, Vinci M, Carmona G, Bianchi ME, Vajkoczy P, et al. High-mobility group box 1 activates integrin-dependent homing of endothelial progenitor cells. Circul Res 2007; 100: 204-12. (Pubitemid 46208720)
25. Crack PJ, Bray PJ. Toll-like receptors in the brain and their potential roles in neuropathology. Immunol Cell Biol 2007; 85: 476-80. (Pubitemid 47367513)
26. Czura CJ, Wang H, Tracey KJ. Dual roles for HMGB1: DNA binding and cytokine. J Endotoxin Res 2001; 7: 315-21. (Pubitemid 33041072)
27. Drexler SK, Foxwell BM. The role of Toll-like receptors in chronic inflammation. Int J Biochem Cell Biol 2010; 42: 506-18.
28. Dyck RH, Bogoch II, Marks A, Melvin NR, Teskey GC. Enhanced epilep-togenesis in S100B knockout mice. Brain Res Mol Brain Res 2002; 106: 22-9. (Pubitemid 35223276)
29. Farina C, Krumbholz M, Giese T, Hartmann G, Aloisi F, Meinl E. Preferential expression and function of Toll-like receptor 3 in human astrocytes. J Neuroimmunol 2005; 159: 12-9. (Pubitemid 40126172)
30. Flores-Sarnat L, Sarnat HB, Davila-Gutierrez G, Alvarez A. Hemimegalencephaly: part 2. Neuropathology suggests a disorder of cellular lineage. J Child Neurol 2003; 18: 776-85. (Pubitemid 38016571)
31. Gomez M, Sampson J, Whittemore V. The tuberous sclerosis complex. Oxford: Oxford University Press; 1999.
32. Griffin WS, Yeralan O, Sheng JG, Boop FA, Mrak RE, Rovnaghi CR, et al. Overexpression of the neurotrophic cytokine S100 beta in human temporal lobe epilepsy. J Neurochem 1995; 65: 228-33.
33. Hayakawa K, Arai K, Lo EH. Role of ERK map kinase and CRM1 in IL-1beta-stimulated release of HMGB1 from cortical astrocytes. Glia 2010; 58: 1007-15.
34. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov 2010; 9: 293-307.
35. Hreggvidsdottir HS, Ostberg T, Wahamaa H, Schierbeck H, Aveberger AC, Klevenvall L, et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 2009; 86: 655-62.
36. Huttunen HJ, Kuja-Panula J, Rauvala H. Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J Biol Chem 2002; 277: 38635-46. (Pubitemid 35154724)
37. Iyer A, Zurolo E, Spliet WG, van Rijen PC, Baayen JC, Gorter JA, et al. Evaluation of the innate and adaptive immunity in type I and type II focal cortical dysplasias. Epilepsia 2010a; 51: 1763-73.
38. Iyer AM, Zurolo E, Boer K, Baayen JC, Giangaspero F, Arcella A, et al. Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies. Neuroscience 2010b; 19: 929-45.
39. Karlen Y, McNair A, Perseguers S, Mazza C, Mermod N. Statistical significance of quantitative polymerase chain reaction. BMC Bioinformatics 2007; 8: 131.
40. Kawai T, Akiraa S. Signaling to NF-/cB by Toll-like receptors. Trends Mol Med 2007; 13: 460-9.
41. Kielian T. Toll-like receptors in central nervous system glial inflammation and homeostasis. J Neurosci Res 2006; 83: 711-30.
42. Kim JB, Sig Choi J, Yu YM, Nam K, Piao CS, Kim SW, et al. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci 2006; 26: 6413-21. (Pubitemid 44318322)
43. Lamparello P, Baybis M, Pollard J, Hol EM, Eisenstat DD, Aronica E, et al. Developmental lineage of cell types in cortical dysplasia with balloon cells. Brain 2007; 130: 2267-76. (Pubitemid 47327637)
44. Lim HK, Choi YA, Park W, Lee T, Ryu SH, Kim SY, et al. Phosphatidic acid regulates systemic inflammatory responses by modulating the Akt-mammalian target of rapamycin-p70 S6 kinase 1 pathway. J Biol Chem 2003; 278: 45117-27. (Pubitemid 37432644)
45. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK. WHO classification of tumours of the central nervous system. Lyon: IARC; 2007.
46. Lue LF, Yan SD, Stern DM, Walker DG. Preventing activation of receptor for advanced glycation end products in Alzheimer's disease. Curr Drug Targets-CNS Neurol Disord 2005; 4: 249-66. (Pubitemid 40754161)
47. Ma L, Nicholson LF. Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus. Brain Res 2004; 1018: 10-7. (Pubitemid 38942855)
48. Mallard C, Wang X, Hagberg H. The role of Toll-like receptors in perinatal brain injury. Clin Perinatol 2009; 36: 763-72.
49. Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010; 16: 413-9.
50. Martinian L, Boer K, Middeldorp J, Hol EM, Sisodiya SM, Squier W, et al. Expression patterns of glial fibrillary acidic protein (GFAP)-delta in epilepsy-associated lesional pathologies. Neuropathol Appl Neurobiol 2009; 35: 394-405.
51. Moddel G, Jacobson B, Ying Z, Janigro D, Bingaman W, Gonzalez-Martinez J, et al. The NMDA receptor NR2B subunit contributes to epileptogenesis in human cortical dysplasia. Brain Res 2005; 1046: 10-23. (Pubitemid 40775869)
52. Mouri F, Tsukada J, Mizobe T, Higashi T, Yoshida Y, Minami Y, et al. Intracellular HMGB1 transactivates the human IL1B gene promoter through association with an Ets transcription factor PU.1. Eur J Haematol 2008; 80: 10-9. (Pubitemid 350265232)
53. Muller S, Ronfani L, Bianchi ME. Regulated expression and subcellular localization of HMGB1, a chromatin protein with a cytokine function. J Intern Med 2004; 255: 332-43. (Pubitemid 38315274)
54. Najm IM, Ying Z, Babb T, Mohamed A, Hadam J, LaPresto E, et al. Epileptogenicity correlated with increased N-methyl-D-aspartate receptor subunit NR2A/B in human focal cortical dysplasia. Epilepsia 2000; 41: 971-6. (Pubitemid 30640861)
55. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull 2005; 28: 886-92. (Pubitemid 40740661)
56. O'Neill LA, Bryant CE, Doyle SL. Therapeutic targeting of Toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol Rev 2009; 61: 177-97.
57. Palmini A, Najm I, Avanzini G, Babb T, Guerrini R, Foldvary-Schaefer N, et al. Terminology and classification of the cortical dysplasias. Neurology 2004; 62: S2-8. (Pubitemid 38419835)
58. Palumbo R, Sampaolesi M, De Marchis F, Tonlorenzi R, Colombetti S, Mondino A, et al. Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J Cell Biol 2004; 164: 441-9. (Pubitemid 38174771)
59. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370-7. (Pubitemid 38294612)
60. Pedrazzi M, Patrone M, Passalacqua M, Ranzato E, Colamassaro D, Sparatore B, et al. Selective proinflammatory activation of astrocytes by high-mobility group box 1 protein signaling. J Immunol 2007; 179: 8525-32.
61. Ramakers C, Ruijter JM, Deprez RH, Moorman AF. Assumption-free analysis of quantitative real-time polymerase chain reaction (polymer-ase chain reaction) data. Neurosci Lett 2003; 339: 62-6. (Pubitemid 36263221)
62. Ravizza T, Boer K, Redeker S, Spliet WG, van Rijen PC, Troost D, et al. The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol Dis 2006; 24: 128-43. (Pubitemid 44416213)
63. Ravizza T, Gagliardi B, Noè F, Boer K, Aronica E, Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 2008; 29: 142-60. (Pubitemid 350180489)
64. Ravizza T, Vezzani A. Status epilepticus induces time-dependent neuron-al and astrocytic expression of interleukin-1 receptor type I in the rat limbic system. Neuroscience 2006; 137: 301-8. (Pubitemid 43031496)
65. Riazi K, Galic MA, Pittman QJ. Contributions of peripheral inflammation to seizure susceptibility: cytokines and brain excitability. Epilepsy Res 2010; 89: 34-42.
66. Rodgers KM, Hutchinson MR, Northcutt A, Maier SF, Watkins LR, Barth DS. The cortical innate immune response increases local neuronal excitability leading to seizures. Brain 2009; 132: 2478-86.
67. Sakatani S, Seto-Ohshima A, Itohara S, Hirase H. Impact of S100B on local field potential patterns in anesthetized and kainic acid-induced seizure conditions in vivo. Eur J Neurosci 2007; 25: 1144-54.
68. Sakatani S, Seto-Ohshima A, Shinohara Y, Yamamoto Y, Yamamoto H, Itohara S, et al. Neural-activity-dependent release of S100B from astrocytes enhances kainate-induced gamma oscillations in vivo. J Neurosci 2008; 28: 10928-36.
69. Sasaki N, Toki S, Chowei H, Saito T, Nakano N, Hayashi Y, et al. Immunohistochemical distribution of the receptor for advanced glyca-tion end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001; 888: 256-62. (Pubitemid 32058790)
70. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002; 418: 191-5. (Pubitemid 34773774)
71. Schmitz F, Heit A, Dreher S, Eisenacher K, Mages J, Haas T, et al. Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells. Eur J Immunol 2008; 38: 2981-92.
72. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-88.
73. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, et al. Measurement of protein using bicinchoninic acid [published erratum appears in Anal Biochem 1987;163:279]. Anal Biochem 1985; 150: 76-85.
74. Vezzani A, Balosso S, Maroso M, Zardoni D, Noé F, Ravizza T. ICE/ caspase 1 inhibitors and IL-1beta receptor antagonists as potential therapeutics in epilepsy. Curr Opin Investig Drugs 2010; 11: 43-50.
75. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005; 46: 1724-43. (Pubitemid 44921957)
76. Vezzani A, Ravizza T, Balosso S, Aronica E. Glia as a source of cytokines: implications for neuronal excitability and survival. Epilepsia 2008; 49 (Suppl 2): 24-32. (Pubitemid 351143763)
77. Weichhart T, Saemann MD. The multiple facets of mTOR in immunity. Trends Immunol 2009; 30: 218-26.
78. Wong M. Animal models of focal cortical dysplasia and tuberous sclerosis complex: recent progress toward clinical applications. Epilepsia 2009; 50 (Suppl 9): 34-44.
79. Yang H, Wang H, Czura CJ, Tracey KJ. HMGB1 as a cytokine and therapeutic target. J Endotoxin Res 2002; 8: 469-72.
80. Yasin SA, Latak K, Becherini F, Ganapathi A, Mille K, Campos O, et al. Balloon cells in human cortical dysplasia and tuberous sclerosis: isolation of a pathological progenitor-like cell. Acta Neuropathol 2010; 120: 85-96.
81. Ying Z, Babb TL, Mikuni N, Najm I, Drazba J, Bingaman W. Selective coexpression of NMDAR2A/B and NMDAR1 subunit proteins in dysplastic neurons of human epileptic cortex. Exp Neurol 1999; 159: 409-18. (Pubitemid 29485227)